The abstract is read at the publisher; the summary is JClub's.
High-avidity monoclonal antibodies targeting dsDNA in tumor-bearing mice transiently increased cfDNA and ctDNA recovery without changing tumor fraction, with dsDNA as the key structural target.
- Why it matters: Liquid biopsies are constrained by low ctDNA amounts, limiting cancer detection and monitoring; priming agents aim to boost recoverable ctDNA for better assay sensitivity.
- What they did: The study built a panel of novel cfDNA-binding agents, testing their cfDNA binding, clearance effects, ctDNA recovery, and how they alter cfDNA fragmentation and composition in tumor-bearing mice.
- The result: Priming was strongest for mAbs with high dsDNA avidity; Fc was not required since F(ab')2 retained activity, and dsDNA-binding single-chain agents using sso7d expanded the strategy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.